


PHARMACEUTICAL 2021

Nascent Biotech Inc. Rank 400 of 409





PHARMACEUTICAL 2021

Nascent Biotech Inc. Rank 400 of 409

The relative strengths and weaknesses of Nascent Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nascent Biotech Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,986% points. The greatest weakness of Nascent Biotech Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 875% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,348%, being 993% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	3.2
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,879
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	2,833
Other Liabilities	0
Other Net Income	-557
Property and Equipment	0
Research and Development	294
Revenues	0
Selling, General and Administrative Expense	321

Output Variable	Value in 1000 USD
Assets	3.2
Liabilities	2,879
Expenses	3,447
Stockholders Equity	-2,876
Net Income	-4,004
Comprehensive Net Income	-4,004
Economic Capital Ratio	-1,348%